drugset / Trial / NCT03156738

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

NCT03156738 ↗

Phase 1 Completed 40 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and immunogenicity of MT-2990 in healthy male subjects.

Timeline

Start
2017-05-17
Primary completion
2017-12-29
Completion
2017-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-2990 Unknown — Intravenous

Indications

No indication recorded.